References of excluded studies

1. Chang, J. E., H. Li, M. R. Smith, R. D. Gascoyne, E. M. Paietta, D. T. Yang, R. H. Advani, S. J. Horning and B. S. Kahl (2014). "Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)." Blood 123(11): 1665-1673.
2. Dietrich S, Weidle J, Rieger M, et al. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. Leukemia 2014;28:708-9.
3. Eve, H. E., S. Carey, S. J. Richardson, C. C. Heise, V. Mamidipudi, T. Shi, J. A. Radford, R. L. Auer, S. H. Bullard and S. A. Rule (2012). "Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences." Br J Haematol 159(2): 154-163.
4. Sanchez-Gonzalez, B., E. Gimeno, F. Garcia-Pallarols, A. Ancochea and A. Salar (2014). "Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma." Leuk Lymphoma 55(10): 2384-2386.
5. Schreiber, S., A. Hoellein, T. Decker, S. Jilg, M. Dreyling, C. Peschel and U. Keller (2015). "Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study." Leuk Lymphoma 56(11): 3227-3229.
6. Shin, D. Y., S. J. Kim, D. H. Yoon, Y. Park, J. H. Kong, J. A. Kim, B. S. Kim, H. J. Kim, J. H. Won, S. K. Park and W. S. Kim (2016). "Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis." Cancer Chemother Pharmacol 77(4): 865-873.
7. Till, B. G., H. Li, S. H. Bernstein, R. I. Fisher, W. R. Burack, L. M. Rimsza, J. D. Floyd, M. A. DaSilva, D. F. Moore, Jr., O. Pozdnyakova, S. M. Smith, M. LeBlanc and J. W. Friedberg (2016). "Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601." Br J Haematol 172(2): 208-218.
8. Yan F, Gopal AK, Graf SA. Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma. Costa LJ, ed. *Pharmaceuticals*. 2017;10(1):28.
9. Burki, T. K. (2017). "Maintenance rituximab in mantle-cell lymphoma." Lancet Oncol. 2017;18(11):e647.

Supplement table: Risk of bias of included trials by domains of the Cochrane's tool

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study, author, year | Allocation concealment  | Sequence generation | Blinding (patients, personnel) | Incomplete outcome data | Selective reporting | Other bias; Pharma funding source |
| Doordjuin 201521 | Unclear | Unclear | High risk | Unclear | Low risk  | No funding source reported |
| Forstpointer 200615 | Low risk  | Low risk  | High risk | Low risk  | Low risk  | None |
| Ghielmini 200516-17 | Low risk  | Low risk  | High risk | Low risk  | Low risk  | No funding source reported |
| Kluin-Nelemans 201218 | Low risk  | Low risk  | High risk | Low risk  | Low risk  | Roche Pharmaceuticals, Bayer Schering Pharma, Schering-Plough |
| LeGouill 201719 | Unclear | Unclear | High risk | Low risk  | Low risk  | Roche, Amgen |
| Rummel 201620 | Unclear | Unclear | High risk | Low risk  | Low risk  | No funding source reported |

Figure: Pooled progression free survival with rituximab maintenance compared to no maintenance or interferon alfa.

